Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Recordati Acquires Six OTC Products

4/24/2012 2:45 PM ET

European pharmaceutical group Recordati Tuesday announced the acquisition of the marketing authorizations, the trademarks and additional assets concerning six OTC pharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH & Co. oHG.

The products acquired are JHP-Rödler, BetadormD, Rhinopront, Collomack Topical, Tirgon and Xitix. The 2012 sales for the six products are estimated at around EUR 6 million.

Giovanni Recordati, chairman and CEO of the Recordati Group, said, "The OTC pharmaceutical segment in Germany represents 52 percent share in units of the overall pharmaceutical market."

Recordati added that together with the existing OTC portfolio, the German subsidiary will now be able to better exploit the OTC market potential by building a dedicated sales organization.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply lower at the open, stocks have regained some ground over the course of morning trading on Thursday. The major averages have climbed well off their worst levels of the day but remain stuck in the red. In another upbeat sign for the U.S. housing market, the Commerce Department released a report on Thursday showing that new home sales came in well above economist estimates in the month of April. The report showed that new home sales climbed 2.3 percent to a seasonally adjusted annual rate of 454,000 in April from the revised March rate of 444,000. Consumer sentiment in the euro area increased for the sixth consecutive month in May to its strongest level since the middle of last year, preliminary data from the European Commission showed Thursday. The DG ECFIN flash estimate of the consumer confidence indicator for Eurozone came in at -21.9,...
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.